Rhythm Pharmaceuticals (NASDAQ:RYTM Investor One-year Losses Grow to 18% as the Stock Sheds US$156m This Past Week
Rhythm Pharmaceuticals (NASDAQ:RYTM Investor One-year Losses Grow to 18% as the Stock Sheds US$156m This Past Week
It is a pleasure to report that the Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is up 35% in the last quarter. But in truth the last year hasn't been good for the share price. After all, the share price is down 18% in the last year, significantly under-performing the market.
我很高興地報告,節奏製藥公司。納斯達克(Sequoia Capital:RYTM)上季度上漲了35%。但事實上,過去一年對股價並不有利。畢竟,該公司股價在過去一年下跌了18%,表現明顯遜於大盤。
With the stock having lost 11% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
鑑於該公司股價在過去一週下跌了11%,我們有必要看看公司的業績,看看是否有什麼危險信號。
Check out our latest analysis for Rhythm Pharmaceuticals
查看我們對Rhythm製藥公司的最新分析
Because Rhythm Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
由於Rhythm PharmPharmticals在過去12個月中出現虧損,我們認為市場可能更關注收入和收入增長,至少目前是這樣。未盈利公司的股東通常預期營收增長強勁。這是因為快速的收入增長可以很容易地推斷出預期利潤,通常是相當大的規模。
In the last year Rhythm Pharmaceuticals saw its revenue grow by 226%. That's a strong result which is better than most other loss making companies. Given the revenue growth, the share price drop of 18% seems quite harsh. Our sympathies to shareholders who are now underwater. On the bright side, if this company is moving profits in the right direction, top-line growth like that could be an opportunity.
去年,Rhythm製藥公司的收入增長了226%。這是一個強勁的結果,比大多數其他虧損的公司都要好。考慮到營收的增長,股價下跌18%似乎相當苛刻。我們對現在深陷困境的股東表示同情。好的一面是,如果這家公司將利潤轉移到正確的方向,那麼這樣的營收增長可能是一個機會。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
您可以在下圖中看到收益和收入隨時間的變化(單擊圖表查看確切的值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231005/0-7c191d9f532aec11e322f48bc211d264-0-10c1d1bdfc014559be6b4b7f07af20e0.png/big)
If you are thinking of buying or selling Rhythm Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.
如果你正在考慮買賣Rhythm PharmPharmticals的股票,你應該看看這個免費關於其資產負債表的詳細報告。
A Different Perspective
不同的視角
Investors in Rhythm Pharmaceuticals had a tough year, with a total loss of 18%, against a market gain of about 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 2% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Rhythm Pharmaceuticals you should know about.
Rhythm PharmPharmticals的投資者經歷了艱難的一年,總虧損18%,而市場收益約為12%。然而,請記住,即使是最好的股票,在12個月的時間裡,有時也會表現遜於市場。不幸的是,去年的表現可能預示著尚未解決的挑戰,因為它比過去五年2%的年化損失更糟糕。我們意識到,羅斯柴爾德男爵曾說過,投資者應該“在街上血淋淋的時候買入”,但我們警告投資者,首先應該確保他們購買的是一家高質量的企業。雖然值得考慮市場狀況對股價可能產生的不同影響,但還有其他更重要的因素。例如,考慮一下風險。每家公司都有它們,我們已經發現Rhythm製藥公司的3個警告標誌你應該知道。
Of course Rhythm Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
當然了節奏製藥可能不是買入的最佳股票那就是。所以你可能想看看這個免費成長型股票的集合。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.